Do analysts prefer CASI or CERO?

CERo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 468,650.00%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than CASI Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CERo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CASI or CERO more profitable?

CERo Therapeutics has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. Company Net Margins Return on Equity Return on Assets CASI Pharmaceuticals -183.93% N/A -131.54% CERo Therapeutics N/A N/A -209.40%

Do analysts recommend SPRC or CERO?

CERo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 468,650.00%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than SciSparc. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CERo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, SPRC or CERO?

CERo Therapeutics has lower revenue, but higher earnings than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SciSparc $679K 1.67 -$12.18M N/A N/A CERo Therapeutics N/A N/A -$8.30M -$9.84 N/A

Is SPRC or CERO more profitable?

Company Net Margins Return on Equity Return on Assets SciSparc N/A N/A N/A CERo Therapeutics N/A N/A -209.40%

Do analysts recommend SILO or CERO?

CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 468,650.00%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Silo Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CERo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CERO or CANF more profitable?

Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% Can-Fite BioPharma N/A N/A N/A

Do analysts recommend JUNS or CERO?

CERo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 468,650.00%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CERo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is JUNS or CERO more profitable?

Company Net Margins Return on Equity Return on Assets Jupiter Neurosciences N/A N/A -246.66% CERo Therapeutics N/A N/A -209.40%

CERo Therapeutics (CERO) Competitors

$0.0070 +0.00 (+9.38%)

As of 09:35 AM Eastern

Compare

CERO vs. CASI, SPRC, SILO, CANF, and JUNS

Should you buy CERo Therapeutics stock or one of its competitors? CERo Therapeutics's main competitors and comparable companies include CASI Pharmaceuticals (CASI), SciSparc (SPRC), Silo Pharma (SILO), Can-Fite BioPharma (CANF), and Jupiter Neurosciences (JUNS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CERo Therapeutics compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

In the previous week, CERo Therapeutics' average media sentiment score of 1.22 beat CASI Pharmaceuticals' score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
CERo Therapeutics	Positive

CERo Therapeutics has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A

CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CERo Therapeutics has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
CERo Therapeutics	N/A	N/A	-209.40%

CERo Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 468,650.00%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CERo Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

CERo Therapeutics beats CASI Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does CERo Therapeutics compare to SciSparc?

SciSparc (NASDAQ:SPRC) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

SciSparc has a beta of 2.83, suggesting that its stock price is 183% more volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

CERo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 468,650.00%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CERo Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
CERo Therapeutics	N/A	N/A	-209.40%

In the previous week, SciSparc had 13 more articles in the media than CERo Therapeutics. MarketBeat recorded 13 mentions for SciSparc and 0 mentions for CERo Therapeutics. CERo Therapeutics' average media sentiment score of 1.22 beat SciSparc's score of 0.76 indicating that CERo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
SciSparc	Positive
CERo Therapeutics	Positive

CERo Therapeutics has lower revenue, but higher earnings than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$679K	1.67	-$12.18M	N/A	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A

Summary

SciSparc and CERo Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does CERo Therapeutics compare to Silo Pharma?

Silo Pharma (NASDAQ:SILO) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Silo Pharma has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

CERo Therapeutics has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. CERo Therapeutics' return on equity of 0.00% beat Silo Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
CERo Therapeutics	N/A	N/A	-209.40%

In the previous week, Silo Pharma had 2 more articles in the media than CERo Therapeutics. MarketBeat recorded 2 mentions for Silo Pharma and 0 mentions for CERo Therapeutics. Silo Pharma's average media sentiment score of 1.66 beat CERo Therapeutics' score of 1.22 indicating that Silo Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Silo Pharma	Very Positive
CERo Therapeutics	Positive

CERo Therapeutics has a consensus target price of $30.00, indicating a potential upside of 468,650.00%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CERo Therapeutics is more favorable than Silo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CERo Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Silo Pharma has higher revenue and earnings than CERo Therapeutics. Silo Pharma is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$54.08K	35.24	-$4.23M	-$4.36	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A

Summary

Silo Pharma beats CERo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does CERo Therapeutics compare to Can-Fite BioPharma?

CERo Therapeutics (NASDAQ:CERO) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

CERo Therapeutics has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Can-Fite BioPharma	N/A	N/A	N/A

In the previous week, CERo Therapeutics' average media sentiment score of 1.22 beat Can-Fite BioPharma's score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CERo Therapeutics	Positive
Can-Fite BioPharma	Neutral

CERo Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 468,650.00%. Can-Fite BioPharma has a consensus price target of $44.00, indicating a potential upside of 2,278.38%. Given CERo Therapeutics' higher possible upside, equities analysts clearly believe CERo Therapeutics is more favorable than Can-Fite BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Can-Fite BioPharma has higher revenue and earnings than CERo Therapeutics. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A
Can-Fite BioPharma	$405K	4.89	-$7.63M	-$14.80	N/A

Summary

Can-Fite BioPharma beats CERo Therapeutics on 7 of the 12 factors compared between the two stocks.

How does CERo Therapeutics compare to Jupiter Neurosciences?

Jupiter Neurosciences (NASDAQ:JUNS) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

CERo Therapeutics has lower revenue, but higher earnings than Jupiter Neurosciences. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20K	142.87	-$8.65M	-$19.12	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A

In the previous week, Jupiter Neurosciences had 3 more articles in the media than CERo Therapeutics. MarketBeat recorded 3 mentions for Jupiter Neurosciences and 0 mentions for CERo Therapeutics. CERo Therapeutics' average media sentiment score of 1.22 beat Jupiter Neurosciences' score of 0.60 indicating that CERo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Jupiter Neurosciences	Positive
CERo Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CERo Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

29.6% of CERo Therapeutics shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	N/A	-246.66%
CERo Therapeutics	N/A	N/A	-209.40%

Jupiter Neurosciences has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Summary

CERo Therapeutics beats Jupiter Neurosciences on 7 of the 11 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERO vs. The Competition

Export

Metric	CERo Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$501K	$12.71B	$7.43B	$12.86B
Dividend Yield	N/A	2.62%	2.51%	19.61%
P/E Ratio	0.00	805.25	274.94	25.22
Price / Sales	N/A	944.25	623.57	99.68
Price / Cash	N/A	83.43	76.19	51.56
Price / Book	0.00	9.23	10.40	5.96
Net Income	-$8.30M	$2.85B	$3.50B	$380.92M
7 Day Performance	N/A	-4.03%	-3.89%	-3.33%
1 Month Performance	N/A	-7.20%	-7.10%	-5.34%
1 Year Performance	N/A	-4.82%	1.70%	-4.58%

CERo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERO CERo Therapeutics	1.3691 of 5 stars	$0.01 +9.4%	$30.00 +428,471.4%	-99.8%	$501K	N/A	N/A	8	Positive News Gap Down
CASI CASI Pharmaceuticals	N/A	$0.21 flat	N/A	N/A	$2.55M	$26.85M	N/A	180
SPRC SciSparc	0.4531 of 5 stars	$4.33 -0.7%	N/A	-94.8%	$2.47M	$679K	N/A	3	Trending News Gap Down
SILO Silo Pharma	0.7817 of 5 stars	$1.45 -2.7%	N/A	-87.9%	$2.37M	$54.08K	N/A	3	Positive News
CANF Can-Fite BioPharma	1.3982 of 5 stars	$2.14 flat	$44.00 +1,956.1%	-82.5%	$2.29M	$405K	N/A	5

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERO) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CERo Therapeutics (CERO) Competitors

CERO vs. CASI, SPRC, SILO, CANF, and JUNS

How does CERo Therapeutics compare to CASI Pharmaceuticals?

Summary

How does CERo Therapeutics compare to SciSparc?

Summary

How does CERo Therapeutics compare to Silo Pharma?

Summary

How does CERo Therapeutics compare to Can-Fite BioPharma?

Summary

How does CERo Therapeutics compare to Jupiter Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO vs. The Competition

CERo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CERo Therapeutics (CERO) Competitors

CERO vs. CASI, SPRC, SILO, CANF, and JUNS

How does CERo Therapeutics compare to CASI Pharmaceuticals?

Does the media refer more to CASI or CERO?

Which has better earnings and valuation, CASI or CERO?

Which has more risk & volatility, CASI or CERO?

Do insiders and institutionals hold more shares of CASI or CERO?

Is CASI or CERO more profitable?

Do analysts prefer CASI or CERO?

Summary

How does CERo Therapeutics compare to SciSparc?

Do insiders and institutionals have more ownership in SPRC or CERO?

Which has more risk & volatility, SPRC or CERO?

Do analysts recommend SPRC or CERO?

Is SPRC or CERO more profitable?

Does the media refer more to SPRC or CERO?

Which has preferable valuation and earnings, SPRC or CERO?

Summary

How does CERo Therapeutics compare to Silo Pharma?

Which has more risk & volatility, SILO or CERO?

Is SILO or CERO more profitable?

Does the media refer more to SILO or CERO?

Do analysts recommend SILO or CERO?

Do insiders & institutionals have more ownership in SILO or CERO?

Which has preferable valuation & earnings, SILO or CERO?

Summary

How does CERo Therapeutics compare to Can-Fite BioPharma?

Which has more volatility & risk, CERO or CANF?

Is CERO or CANF more profitable?

Does the media favor CERO or CANF?

Do analysts recommend CERO or CANF?

Do insiders and institutionals believe in CERO or CANF?

Which has higher earnings and valuation, CERO or CANF?

Summary

How does CERo Therapeutics compare to Jupiter Neurosciences?

Which has stronger earnings & valuation, JUNS or CERO?

Does the media favor JUNS or CERO?

Do analysts recommend JUNS or CERO?

Do insiders and institutionals believe in JUNS or CERO?

Is JUNS or CERO more profitable?

Which has more risk & volatility, JUNS or CERO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO vs. The Competition

CERo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools